CCNE1 Is a Novel Synthetic Lethal Target for ARID1A-Mutated Ovarian Clear Cell Carcinoma

被引：0
|
作者：
Kawahara, Naoki [1 ]
Yamada, Yuki [1 ]
Kawaguchi, Ryuji [1 ]
机构：
[1] Nara Med Univ, Dept Obstet & Gynecol, Nara, Japan
来源：
CANCER SCIENCE | 2023年 / 114卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-3026
引用
收藏
页码：1845 / 1845
页数：1
相关论文
共 50 条
  • [31] Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers
    Bitler, Benjamin G.
    Aird, Katherine M.
    Garipov, Azat
    Li, Hua
    Amatangelo, Michael
    Kossenkov, Andrew V.
    Schultz, David C.
    Liu, Qin
    Shih, Ie-Ming
    Conejo-Garcia, Jose R.
    Speicher, David W.
    Zhang, Rugang
    NATURE MEDICINE, 2015, 21 (03) : 231 - +
  • [32] Epigenetic synthetic lethality in ovarian clear cell carcinoma: EZH2 and ARID1A mutations
    Bitler, Benjamin G.
    Aird, Katherine M.
    Zhang, Rugang
    MOLECULAR & CELLULAR ONCOLOGY, 2016, 3 (01):
  • [33] HDAC6 AS A THERAPEUTIC TARGET FOR OVARIAN CLEAR CELL CARCINOMA, IN ASSOCIATION WITH ARID1A LOSS
    Yano, M.
    Yasuda, M.
    Miyazawa, M.
    Miwa, M.
    Hasegawa, K.
    Narahara, H.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2018, 28 : 874 - 874
  • [34] Treatment Strategies for ARID1A-Deficient Ovarian Clear Cell Carcinoma
    Takahashi, Kazuaki
    Takenaka, Masataka
    Okamoto, Aikou
    Bowtell, David D. L.
    Kohno, Takashi
    CANCERS, 2021, 13 (08)
  • [35] ARID1A expression in ovarian clear cell carcinoma with an adenofibromatous component
    Nishikimi, Kyoko
    Kiyokawa, Takako
    Tate, Shinichi
    Iwamoto, Masami
    Shozu, Makio
    HISTOPATHOLOGY, 2015, 67 (06) : 866 - 871
  • [36] Clinicopathological Significance of ARID1A Immunoreactivity in Ovarian Clear Cell Carcinoma
    Maeda, D.
    Mao, T-L
    Fukayama, M.
    Wang, T-L
    Shih, I-M
    MODERN PATHOLOGY, 2011, 24 : 259A - 259A
  • [37] CCNE1 amplification as marker of poor prognosis and novel therapeutic target in advanced breast cancer
    Marra, Antonio
    Selenica, Pier
    Zhu, Yingjie
    Safonov, Anton
    Razavi, Pedram
    Roulston, Anne
    Koehler, Maria
    Curigliano, Giuseppe
    Ross, Dara S.
    Weigelt, Britta
    Reis-Filho, Jorge
    Schram, Alison M.
    Chandarlapaty, Sarat
    Rosen, Ezra
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [38] Identification of novel biomarkers of response to ATR inhibitors in ARID1A mutant ovarian clear cell carcinoma
    Stewart, J. R.
    Baxter, J.
    Zatreanu, D.
    Brough, R.
    Song, F.
    Konde, A.
    Krastev, D.
    Alexander, J.
    Natrajan, R.
    Pettitt, S.
    Banerjee, S.
    Lord, C.
    ANNALS OF ONCOLOGY, 2022, 33 : S383 - S384
  • [39] Histone Deacetylase Inhibition Has Targeted Clinical Benefit in ARID1A-Mutated Advanced Urothelial Carcinoma
    Gupta, Sumati
    Albertson, Daniel J.
    Parnell, Timothy J.
    Butterfield, Andrew
    Weston, Alexis
    Pappas, Lisa M.
    Dalley, Brian
    O'Shea, John M.
    Lowrance, William T.
    Cairns, Bradley R.
    Schiffman, Joshua D.
    Sharma, Sunil
    MOLECULAR CANCER THERAPEUTICS, 2019, 18 (01) : 185 - 195
  • [40] Therapeutic preferability of gemcitabine for ARID1A-deficient ovarian clear cell carcinoma
    Kuroda, Takafumi
    Ogiwara, Hideaki
    Sasaki, Mariko
    Takahashi, Kazuaki
    Yoshida, Hiroshi
    Kiyokawa, Takako
    Sudo, Kazuki
    Tamura, Kenji
    Kato, Tomoyasu
    Okamoto, Aikou
    Kohno, Takashi
    GYNECOLOGIC ONCOLOGY, 2019, 155 (03) : 489 - 498
12345